Receptor selectivity
Foundational research compares ipamorelin with earlier growth-hormone secretagogues, examining the selective receptor signaling profile under the conditions of the pharmacology study.
GLPZone / The research collection
Illustrative certificateNS-2026-06045Nordicstar Analytical Sciences
Ipamorelin 5 MG
99.772%HPLC purity
- Lot
- GLZ-26-IPA-1044
- Measured content
- 5.04 mg
- Mass-spec identity
- Confirmed
- Endotoxin
- <1.0 EU/mg
- Tested
- 25 Sep 2026
Illustrative certificateNS-2026-06046Nordicstar Analytical Sciences
Ipamorelin 10 MG
99.734%HPLC purity
- Lot
- GLZ-26-IPA-1045
- Measured content
- 10.07 mg
- Mass-spec identity
- Confirmed
- Endotoxin
- <1.0 EU/mg
- Tested
- 24 Sep 2026
Repair & Recovery
Ipamorelin
Ghrelin receptor pharmacology & secretagogue selectivity
A pair saves 10%. A set of three saves 15%.
For laboratory research use only.
Not for human consumption or clinical use.
Compound details
- Compound
- Ipamorelin
- CAS number
- 170851-70-4
- Molecular formula
- C38H49N9O5
- Molecular weight
- 711.86 g/mol
- Form
- Lyophilized
Quality & documentation
The records shown here are illustrative. Request laboratory-issued documentation for your lot before ordering.
- Lot
- GLZ-26-IPA-1044
- HPLC purity
- 99.772%
- Measured content
- 5.04 mg
- Tested
- 25 Sep 2026
- Report
- NS-2026-06045
- Lot
- GLZ-26-IPA-1045
- HPLC purity
- 99.734%
- Measured content
- 10.07 mg
- Tested
- 24 Sep 2026
- Report
- NS-2026-06046
Shipping & handling
Priority, tracked shipping within the United States, free on orders of $200 or more after savings. Add Priority dispatch at checkout to have your order packed first; Private Clients receive it on every order. Follow the product documentation for laboratory handling requirements.
Shipping information01 / The compound
Understand
the starting point.
Ghrelin receptor pharmacology & secretagogue selectivity
Ipamorelin, also known by the development code NNC-26-0161, is a synthetic five-residue peptide originally described as a selective growth hormone secretagogue.
Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Early pharmacology studies examined its ability to stimulate growth hormone release through the growth hormone secretagogue receptor pathway and compared its activity with earlier GHRP compounds.
Ipamorelin is a pentapeptide growth-hormone secretagogue studied for its interaction with the growth hormone secretagogue receptor, GHS-R1a. Research has examined its receptor selectivity, signaling behavior and biological activity across laboratory and animal models.
Its research interest comes in part from comparisons with other growth-hormone secretagogues and from studies examining how GHS-R1a activation can influence downstream signaling pathways under controlled experimental conditions.
02 / Research profile
The pathways.
The possibilities.
Ipamorelin is studied as an agonist of the ghrelin/growth hormone secretagogue receptor pathway. Activation of this receptor pathway has been investigated for its role in growth hormone research and other physiological signaling processes.
Ipamorelin belongs to the growth hormone secretagogue family and is mechanistically distinct from GHRH analogues, which interact with the growth hormone-releasing hormone pathway instead.
Skeletal biology
Animal research has examined ipamorelin in skeletal and bone-formation models. These endpoints provide context for the individual compound, not an established effect of a commercial preparation.
Gastrointestinal motility
Preclinical studies also examine gastrointestinal signaling and postoperative intestinal-motility models, illustrating that GHS-R1a-related research extends beyond a single growth-hormone endpoint.
Reading the evidence
Published Ipamorelin research includes in-vitro experiments and animal models examining receptor pharmacology, secretagogue selectivity, skeletal biology and gastrointestinal motility. Evidence varies by research question and experimental system, so findings should be interpreted within the specific models and conditions studied. Findings from laboratory and animal studies should be interpreted within the experimental systems, species and conditions tested. They do not establish the properties of GLPZone material outside those research settings.
03 / Reference data
The details,
in plain sight.
Reference specifications describe a compound. The final lot documentation identifies the material supplied.
| Compound | Ipamorelin |
|---|---|
| Research area | Repair & Recovery |
| CAS number | 170851-70-4 |
| Molecular formula | C38H49N9O5 |
| Molecular weight | 711.86 g/mol |
| Physical form | Lyophilized |
| Vial options | 5 MG · 10 MG |
| Intended use | Laboratory research only |
Variant amounts are nominal catalog quantities. They are not instructions for use.
What is in the sample?
HPLC separates components under a defined method. Read the reported percentage alongside the chromatogram, wavelength, integration method, and scope of the test.
Is it the expected compound?
Mass spectrometry provides molecular-mass evidence. Identity and chromatographic purity answer different questions; one cannot stand in for the other.
Does the report match the vial?
Connect the product name, variant, lot identifier, report date, and issuing laboratory. A report is useful only when its sample can be linked to the material being reviewed.
Independent analysis
Every Ipamorelin lot is analyzed by Nordicstar Analytical Sciences for identity, content, and purity by HPLC with LC-MS confirmation. Each certificate carries a report number and verification key that can be checked at nordicstarlabs.com/verify. Research references below describe published science, not a certificate for a vial.
Read a COA with confidence| Presentation | Lot | HPLC purity | Tested | Certificate |
|---|---|---|---|---|
| 5 MG Current lot | GLZ-26-IPA-1044 | 99.772% | 25 Sep 2026 | NS-2026-06045 |
| 10 MG Current lot | GLZ-26-IPA-1045 | 99.734% | 24 Sep 2026 | NS-2026-06046 |
| 5 MG | GLZ-26-IPA-756 | 99.723% | 20 Aug 2026 | NS-2026-06161 |
| 10 MG | GLZ-26-IPA-755 | 99.578% | 10 Aug 2026 | NS-2026-06163 |
| 5 MG | GLZ-26-IPA-656 | 99.761% | 17 Jul 2026 | NS-2026-06162 |
| 10 MG | GLZ-26-IPA-655 | 99.754% | 11 Jul 2026 | NS-2026-06164 |
05 / Storage & handling
Care for
the material.
Store Ipamorelin according to the conditions specified on the applicable product documentation and lot-specific Certificate of Analysis. Protect research material from unnecessary exposure to heat, moisture and light.
For experimental storage or stability requirements, researchers should follow validated laboratory procedures appropriate to their protocol and material form.
Explore the handling guide06 / Common questions
A little more
understanding.
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue originally developed under the code NNC-26-0161. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH₂ and it has been investigated for its activity within the growth hormone secretagogue/ghrelin receptor pathway.
Is Ipamorelin a peptide?
Yes. Ipamorelin is a synthetic pentapeptide, meaning its structure contains five amino-acid or amino-acid-derived residues.
How many amino acids are in Ipamorelin?
Ipamorelin is composed of five residues represented by the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂.
What pathway is Ipamorelin studied in?
Ipamorelin is studied within the ghrelin/growth hormone secretagogue receptor pathway, which is involved in signaling associated with growth hormone secretion.
Is Ipamorelin the same as CJC-1295?
No. Ipamorelin is a growth hormone secretagogue associated with the ghrelin/GHS receptor pathway. CJC-1295 is a GHRH analogue associated with the growth hormone-releasing hormone pathway. They are distinct compounds with different structures and mechanisms of research interest.
07 / Further reading
Go to
the source.
Selected literature for context. Read each study’s methods, experimental model, and limitations alongside its findings.
- 01
- 02Andersen NB, Malmlöf K, Johansen PB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research. 2001;11(5):266–272. PMID: 11735244. DOI: 10.1054/ghir.2001.0239 pubmed.ncbi.nlm.nih.gov / Published literature
- 03Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics. 2009;329(3):1110–1116. PMID: 19289567. DOI: 10.1124/jpet.108.149211 pubmed.ncbi.nlm.nih.gov / Published literature
Curated pairings
